BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
BioStem Technologies Reports First Quarter 2026 Financial Results
BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
BioStem Technologies Expands Product Access in Medicaid
BioStem Technologies Reports Third Quarter 2025 Financial Results
BioStem Technologies Announces Filing of Restated Financial Statements
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters
BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers
BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025